La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Indoco Remedies Crescita futura

Future criteri di controllo 4/6

Si prevede che Indoco Remedies aumenterà gli utili e i ricavi rispettivamente del 43.7% e 10.4% all'anno, mentre si prevede che l'EPS crescerà del 48.6% all'anno.

Informazioni chiave

43.7%

Tasso di crescita degli utili

48.6%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	18.0%
Tasso di crescita dei ricavi	10.4%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	25 Jul 2024

Aggiornamenti recenti sulla crescita futura

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Recent updates

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

May 24

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Jan 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Sep 16

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

May 21

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Aug 31

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Jul 04

Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price

Mar 09

What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?

Feb 22

Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?

Feb 07

Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 17

Is Indoco Remedies (NSE:INDOCO) A Risky Investment?

Dec 27

Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)

Dec 06

What Type Of Shareholders Own The Most Number of Indoco Remedies Limited (NSE:INDOCO) Shares?

Nov 14

Investors Who Bought Indoco Remedies (NSE:INDOCO) Shares A Year Ago Are Now Up 66%

Oct 19

These 4 Measures Indicate That Indoco Remedies (NSE:INDOCO) Is Using Debt Reasonably Well

Sep 14

Previsioni di crescita degli utili e dei ricavi

NSEI:INDOCO - Stime future degli analisti e dati finanziari passati (INR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2026	21,757	1,657	814	N/A	5
3/31/2025	19,148	1,086	689	N/A	5
6/30/2024	18,223	767	N/A	N/A	N/A
3/31/2024	18,173	985	-2,706	1,567	N/A
12/31/2023	17,958	1,016	N/A	N/A	N/A
9/30/2023	17,356	1,134	-911	1,442	N/A
6/30/2023	16,869	1,281	N/A	N/A	N/A
3/31/2023	16,686	1,423	-284	1,788	N/A
12/31/2022	16,496	1,569	N/A	N/A	N/A
9/30/2022	16,084	1,617	85	1,703	N/A
6/30/2022	15,622	1,537	N/A	N/A	N/A
3/31/2022	15,408	1,548	485	1,738	N/A
12/31/2021	14,368	1,393	N/A	N/A	N/A
9/30/2021	14,110	1,317	257	1,391	N/A
6/30/2021	13,524	1,157	N/A	N/A	N/A
3/31/2021	12,415	930	54	822	N/A
12/31/2020	12,084	734	N/A	N/A	N/A
9/30/2020	11,654	571	387	931	N/A
6/30/2020	11,298	393	N/A	N/A	N/A
3/31/2020	11,066	241	644	1,228	N/A
12/31/2019	10,909	302	N/A	N/A	N/A
9/30/2019	10,640	264	N/A	N/A	N/A
6/30/2019	10,071	111	N/A	N/A	N/A
3/31/2019	9,684	-29	352	1,321	N/A
3/31/2018	10,424	412	N/A	1,227	N/A
3/31/2017	10,968	771	N/A	886	N/A
3/31/2016	10,081	819	N/A	1,122	N/A
3/31/2015	8,570	828	N/A	1,090	N/A
3/31/2014	7,336	580	N/A	988	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di INDOCO ( 43.7% all'anno) è superiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Si prevede che gli utili di INDOCO ( 43.7% all'anno) cresceranno più rapidamente del mercato Indian ( 16.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di INDOCO cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di INDOCO ( 10.4% all'anno) crescerà più rapidamente del mercato Indian ( 10% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di INDOCO ( 10.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di INDOCO è previsto essere elevato tra 3 anni

Indoco Remedies Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 11%

Recent updates

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

Consensus EPS estimates fall by 20%

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

Consensus EPS estimates fall by 16%

Full year 2024 earnings: EPS misses analyst expectations

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Consensus EPS estimates fall by 13%

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021)

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Investor sentiment improved over the past week

Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?

Chief Financial Officer Mandar Borkar has left the company

Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly

Full year 2021 earnings released: EPS ₹10.10 (vs ₹2.62 in FY 2020)

Indoco Remedies Limited Recommends Dividend for the Financial Year 2020-2021